Regoli F, et al. - In a prospective, multicenter, observational study (4P) run in 10 Swiss implanting centers, researchers assessed the performance of recent generation implantable cardioverter defibrillator (ICD) equipped with SmartShock technology (SST) for detection and conversion of ventricular tachyarrhythmias (VTA). A total of 196 patients were analyzed; mean follow-up was 27.7 months (452 patient-years of observation). High efficacy of anti-tachycardia pacing (ATP) was observed, which was the first-line therapy; rescue shocks were rare. Findings revealed frequent episodes of VTA in a cohort of non-trial, unselected ICD patients. The strength of VTA detection by SST was corroborated in this study, as well as the efficacy of ATP therapy, thus, limiting the overall ICD shock burden.